V. Perrone, Melania Dovizio, Melania Leogrande, Antonella Tamma, M. Giovannitti, Carlotta Buzzoni, L. Esposti
{"title":"Patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a real-world study in Italy","authors":"V. Perrone, Melania Dovizio, Melania Leogrande, Antonella Tamma, M. Giovannitti, Carlotta Buzzoni, L. Esposti","doi":"10.2217/bmt-2023-0020","DOIUrl":null,"url":null,"abstract":"Aim: Italian real-world analysis of CDK4/6 inhibitor (CDK4/6i) treatment in HR+/HER2- metastatic breast cancer aimed at evaluating patients' medical history, treatment duration, treatment patterns (combination with endocrine therapy), line of therapy and drug dose variations. Materials & methods: CDK4/6i treatment was analyzed using healthcare administrative databases covering 18% of Italians between January 2017 and June 2022. Results: Among CDK4/6i-treated women, palbociclib and abemaciclib (were more frequently combined with fulvestrant, while ribociclib with aromatase inhibitors. CDK4/6i recommended doses were initiated in 72–90% patients and maintained after 3–6 months in respectively 65–57% women. Frontline CDK4/6i use grew over time (reaching 90%). Median time-to-treatment discontinuation was 11.0 months in palbociclib, 15.9 in abemaciclib and 15.4 in ribociclib cohorts. Conclusion: CDK4/6i plus endocrine therapy is increasingly utilized as first-line therapy, with low proportions of dose reductions within 6 months and discontinuations at 1 year.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":"21 1","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/bmt-2023-0020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: Italian real-world analysis of CDK4/6 inhibitor (CDK4/6i) treatment in HR+/HER2- metastatic breast cancer aimed at evaluating patients' medical history, treatment duration, treatment patterns (combination with endocrine therapy), line of therapy and drug dose variations. Materials & methods: CDK4/6i treatment was analyzed using healthcare administrative databases covering 18% of Italians between January 2017 and June 2022. Results: Among CDK4/6i-treated women, palbociclib and abemaciclib (were more frequently combined with fulvestrant, while ribociclib with aromatase inhibitors. CDK4/6i recommended doses were initiated in 72–90% patients and maintained after 3–6 months in respectively 65–57% women. Frontline CDK4/6i use grew over time (reaching 90%). Median time-to-treatment discontinuation was 11.0 months in palbociclib, 15.9 in abemaciclib and 15.4 in ribociclib cohorts. Conclusion: CDK4/6i plus endocrine therapy is increasingly utilized as first-line therapy, with low proportions of dose reductions within 6 months and discontinuations at 1 year.
期刊介绍：
Breast Cancer Management (ISSN: 1758-1923) addresses key issues in disease management by exploring the best patient-centered clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in the clinic. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Breast Cancer Management provides oncologists and other health professionals with the latest findings and opinions on reducing the burden of this widespread disease. Recent research findings and advances clinical practice in the field are reported and analyzed by international experts. The journal presents this information in clear, accessible formats. All articles are subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal’s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3. Coverage includes: Diagnosis and imaging, Surgical approaches, Radiotherapy, Systemic therapies, Cancer clinical trials, Genetic aspects of disease, Personalized medicine, Translational research and biomarker studies, Management of psychological distress, Epidemiological studies, Pharmacoeconomics, Evidence-based treatment guidelines.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
